Elevance Health (NYSE:ELV) FY Conference Summary Company Overview - **Company**: Elevance Health - **Date of Conference**: March 10, 2026 Key Points CMS Sanctions and Risk Adjustment Practices - **CMS Concerns**: The Centers for Medicare & Medicaid Services (CMS) raised concerns regarding historical risk adjustment data submission practices for services prior to April 2023, indicating a broader policy and payments dispute rather than just a data submission issue [3][4] - **Actions Taken**: Elevance Health has engaged with CMS in good faith, proactively disclosing potentially unverified diagnosis codes and seeking guidance on handling prior year corrections [4][5] - **Current Practices**: The company asserts that its current risk adjustment practices are compliant with CMS regulations and that the issues raised pertain only to historical practices [11][14] - **Financial Impact**: Elevance expects the resolution of this matter will not alter its capital deployment priorities for 2026, maintaining an outlook of at least $5.5 billion in operating cash flow [8][9] Medicare Advantage Business - **2026 Guidance**: The adjusted earnings guidance for 2026 is reaffirmed at a minimum of $25.50 per share, with a benefit expense ratio of approximately 90.2% [16] - **Enrollment Cycle**: A significant portion of the 2026 enrollment cycle is already completed, which helps mitigate in-year financial implications from potential sanctions [10] - **Margin Improvement**: The company anticipates a margin improvement to at least 2% for Medicare Advantage in 2026 [10] Medicaid Trends - **Cost Trends**: Medicaid cost trends have moderated from low double-digit percentages in 2025 to mid-single digits in 2026, driven by changes in acuity and utilization patterns [22][23] - **Operational Initiatives**: Elevance is focusing on tighter medical and pharmacy cost management, expanded behavioral health interventions, and stronger payment integrity to manage costs effectively [24][25] ACA Membership and Effectuation - **Membership Growth**: ACA membership increased by approximately 10% sequentially, with expectations of year-end enrollment at 900,000, down 30% year-over-year [26][30] - **Effectuation Rates**: Effectuation rates for new sales and active renewals are tracking in line with historical patterns, indicating stability in membership activation [26][27] Strategic Direction and Leadership Transition - **Leadership Changes**: The departure of Peter D. Haytaian does not signal a change in strategy for Carelon, which remains integral to Elevance's enterprise strategy [18][19] - **Focus Areas**: The company is prioritizing revenue growth, margin discipline, and enhancing leadership across Carelon's core businesses [19][20] Investment and Technology Initiatives - **Incremental Investments**: Elevance is investing in digital and AI capabilities, scaling Carelon's services, and quality initiatives, with a focus on integrating these technologies across operations [31][32] - **Expected Outcomes**: The company aims for tangible outcomes such as cost reduction, improved cycle times, and productivity gains through these investments [33] Conclusion - **Overall Outlook**: Elevance Health views the CMS sanctions as a historical policy dispute rather than a structural issue affecting its Medicare Advantage business, maintaining confidence in its operational and financial strategies moving forward [15][14]

Star ratings are hard to ignore. Even when we’re looking for quality, our brains steer us toward cheaper stuff online. Christopher @Mims explains why. https://t.co/yTWlWe7Aqn ...